Cann Group Limited
Cann Group Limited
- P/E ratio
- 0.30
Your view on CAN.AX
Overview
What the company does, where it operates, and who runs it.
About Cann Group Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jennifer Lee Pilcher
- Headquarters
- 23 Greentek Court, Mildura, VIC, AU
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jennifer Lee Pilcher
- Headquarters
- 23 Greentek Court, Mildura, VIC, AU
Cann Group Limited, established in Port Melbourne, Australia, in 2014, specializes in the comprehensive lifecycle of medicinal cannabis. This includes genetic development, cultivation, manufacturing, clinical assessment, and the distribution of therapeutic cannabis products.
The company supplies these products for use within Australia and also exports them to international markets, operating under specific licenses that permit research and the cultivation of cannabis for human medicinal and scientific purposes.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cann Group Limited. Starting points for Cann Group Limited: P/E 0.3, EPS AUD 0.05, beta 0.05 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Cann Group Limited. Cann Group Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cann Group Limited. Trailing twelve-month EPS for Cann Group Limited stands at AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2018 | Next yearYear to Jun 2019 |
|---|---|---|
| Average estimate | −AUD 0.02 | −AUD 0.04 |
| Lowest estimate | −AUD 0.02 | −AUD 0.04 |
| Highest estimate | −AUD 0.02 | −AUD 0.04 |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Revenue estimates
| Total | This yearYear to Jun 2018 | Next yearYear to Jun 2019 |
|---|---|---|
| Average estimate | AUD 4.21M | AUD 2.57M |
| Lowest estimate | AUD 4.21M | AUD 2.57M |
| Highest estimate | AUD 4.21M | AUD 2.57M |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cann Group Limited. Cann Group Limited has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ADR.AXAdherium Limited | Healthcare | Medical - Devices | — | ||
| BGT.AXBio-Gene Technology Limited | Basic Materials | Agricultural Inputs | — | ||
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| ECS.AXECS Botanics Holdings Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| HIQ.AXHITIQ Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| ICR.AXIntelicare Holdings Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| IVX.AXInvion Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BIOIFBiome Grow Inc. | Healthcare | OTC | $56,208 | ||
| BKUHBakhu Holdings, Corp. | Healthcare | OTC | $6.0M | ||
| BLEVFBeleave Inc. | Healthcare | OTC | $566 | ||
| BMCSBioTech Medics, Inc. | Healthcare | OTC | $225,892 | ||
| BMMJBody and Mind Inc. | Healthcare | OTC | $14,769 | ||
| BNXT.CNBioNxt Solutions Inc. | Healthcare | CNQ | $76.7M | ||
| BOIRFBoiron S.A. | Healthcare | OTC | $520.9M | ||
| BP8.AXBPH Global Ltd | Healthcare | ASX | — | ||
| BSPKBespoke Extracts, Inc. | Healthcare | OTC | $2.8M | ||
| BSPMBiostar Pharmaceuticals, Inc. | Healthcare | OTC | $264 | ||
| BUDZWEED, Inc. | Healthcare | OTC | $4.4M | ||
| CAAOFINDVR Brands Inc. | Healthcare | OTC | $3,025 | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cann Group Limited.